Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novosis Leuprorelin 10.72 mg implant versus Trenantone in prostate cancer
2008-001687-37Phase 3Completed
- Sponsor
- Novosis
- Start
- May 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of leuprorelin in prostate cancer (PCa) (2 arms), sponsored by Novosis. Primary endpoint: Area under the curve (AUC) of testosterone levels. Started May 2008; status: completed.
02
Drugs
leuprorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-001687-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001687-37.